Clearline Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Clearline Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-31,151	Closed	-$4.55M	–	114
2023 Q3	$4.55M	Buy	+31,151	New	+$5.86M	0.39%	66

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Clearline Capital's MDGL Position: Q4 2023 in Review

Clearline Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2023, closing a stake of 31,151 shares — an estimated $4.55M sold.

Clearline Capital first reported a position in MDGL in Q3 2023 and held it in 1 quarter. The position peaked at $4.55M in Q3 2023. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

Clearline Capital reported no remaining Madrigal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Clearline Capital sold 31,151 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $4.55M.
Clearline Capital first reported a position in Madrigal Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Clearline Capital's Madrigal Pharmaceuticals position peaked at $4.55M in Q3 2023.
226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on Clearline Capital's 13F filing for Q4 2023, filed 14 Feb 2024.